Judo Bio
- Website
- judo.bio
- Last Round
- Series AOct 2024
- Rounds
- 2
About
Oligonucleotide therapeutics targeting the kidney
Summary
Its most recent funding was a Series A round in Oct 2024. Investors include Atlas Venture, Alexandria Venture Investments and Digitalis Ventures.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.